Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The company is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). The company also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. The company has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).

Moderna, Inc. terlibat dalam pengembangan obat transformatif yang berdasarkan pada asam ribonukleat pengantar (mRNA). Perusahaan ini berkantor pusat di Cambridge, Massachusetts, dan saat ini mempekerjakan 4.700 karyawan penuh waktu. Perusahaan ini melaksanakan penawaran umum perdana (IPO) pada 07 Desember 2018. Perusahaan ini berfokus pada pengembangan obat untuk vaksin penyakit menular, terapi onkologi, dan terapi penyakit langka. Platformnya menggabungkan kemajuan dalam tiga komponen, mRNA, pengantaran, dan proses manufaktur, untuk memajukan obat-obatnya. Produk-produk utamanya adalah Spikevax dan mNEXSPIKE (vaksin COVID-nya), serta mRESVIA (vaksin terhadap virus syncytial pernapasan (RSV)). Perusahaan ini juga memiliki jalur pengembangan yang beragam yang terdiri dari 35 program terapeutik dan vaksin, enam di antaranya berada dalam tahap perkembangan akhir. Perusahaan ini memiliki pengajuan regulasi yang sedang dalam tinjauan untuk vaksin flu musiman+COVID-nya (mRNA-1083) di Eropa dan Kanada serta untuk vaksin flu musiman (mRNA-1010) di Amerika Serikat, Eropa, Kanada, dan Australia. Program penyakit langkanya termasuk Asidemia Propionat (mRNA-3927); Asidemia Metilmalonat (mRNA-3705), dan Fibrosis Kistik (mRNA-3692/VX-522).

Moderna

NVIDIA

Google

Apple

Microsoft

Amazon

Space Exploration Technologies Corp.

Taiwan Semiconductor

Broadcom

Tesla

Meta Platforms

Micron Technology

Berkshire Hathaway

Eli Lilly

Walmart

JPMorgan

ASML

Intel

Visa

Exxon Mobil

Johnson & Johnson

Oracle

Applied Materials

Lam Research

Cisco

Caterpillar

MasterCard

SPDR S&P500 ETF

Costco

Bank of America

AbbVie

General Electric

UnitedHealth Group

Morgan Stanley

Procter & Gamble

Chevron

Coca-Cola

Home Depot

Netflix

Goldman Sachs

Palantir

Vanguard Total Stock Market ETF

Texas Instruments

Royal Bank of Canada

Merck

Philip Morris

Marvell Technology

AstraZeneca

Novartis

Dell

Wells Fargo

Alibaba

Raytheon Technologies

Citigroup

Seagate Technology

QUALCOMM

Linde PLC

Western Digital

Palo Alto Networks

American Express

Shell

Arista Networks

Analog Devices

Toyota

Invesco QQQ Trust

Toronto-Dominion Bank

Banco Santander

McDonald's

T-Mobile

Verizon

PepsiCo

Novo Nordisk

Amgen

NextEra Energy

Disney

TotalEnergies

Boeing

CrowdStrike

BlackRock

Corning

Southern Copper

Anheuser-Busch Inbev

Charles Schwab

Deere

Union Pacific

Abbott

Gilead Sciences

AT&T

Blackstone

Uber

Honeywell

Intuitive Surgical

Pfizer

Shopify

Banco Bilbao

Moderna Stock

About Moderna

Key Statistics

Insights

People Also Bought